ERS Genomics and IRBM sign CRISPR/Cas9 license agreement

FHS
May 21, 2024
5:03 am

ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants IRBM access to ERS’ CRISPR/Cas9 patent portfolio.

Stem cell transplant offers hope for patients with multiple sclerosis

Stem cells harvested from a person’s own bone marrow or blood, can safely slow progression of the most common form of the autoimmune disease, multiple

September 26, 2023

Sandoz unveils global action plan to improve access to biosimilars

As the spotlight trains on access to biosimilars, Novartis’ generics unit on Thursday released a global action plan to boost biosimilar adoption by 2030. The

June 15, 2023

Apple wins FDA nod for hearing aid software for certain Airpods

Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: The Food and Drug Administration

September 13, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.